Amgen has revealed ground-breaking findings from its Phase 3 DeLLphi-304 clinical trial, showing that Imdelltra® (tarlatamab-dlle) dramatically decreased the risk of death in patients with extensive-stage small cell lung cancer (ES-SCLC) by 40% when compared to standard chemotherapy. Patients whose illness had worsened after receiving platinum-based chemotherapy were included in […]
IMDELLTRA®
IMDELLTRA’s safety profile was consistent with the recognized profile. Detailed DeLLphi-304 results will be presented at an upcoming medical congress.
